{'52WeekChange': 0.3764292,
 'SandP52WeekChange': 0.0644362,
 'address1': '430 East 29th Street',
 'address2': 'Suite 1520',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 15.72,
 'askSize': 1300,
 'averageDailyVolume10Day': 95375,
 'averageVolume': 183363,
 'averageVolume10days': 95375,
 'beta': None,
 'beta3Year': None,
 'bid': 15.75,
 'bidSize': 800,
 'bookValue': 5.338,
 'category': None,
 'circulatingSupply': None,
 'city': 'New York',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 15.82,
 'dayLow': 15.3,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -5.328,
 'enterpriseToRevenue': None,
 'enterpriseValue': 396625312,
 'exDividendDate': None,
 'exchange': 'NGM',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 15.639571,
 'fiftyTwoWeekHigh': 19.96,
 'fiftyTwoWeekLow': 7.41,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 9992040,
 'forwardEps': -2.65,
 'forwardPE': -5.90566,
 'fromCurrency': None,
 'fullTimeEmployees': 62,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.18188,
 'heldPercentInstitutions': 0.86143994,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/prevailtherapeutics.com',
 'longBusinessSummary': 'Prevail Therapeutics Inc., a gene therapy company, '
                        'focuses on developing and commercializing '
                        'disease-modifying AAV-based gene therapies for '
                        'patients with neurodegenerative diseases. The '
                        "company's lead product candidate is PR001, which is "
                        'in Phase I/II clinical trial for the treatment of '
                        "Parkinson's disease with GBA1 mutation and "
                        'neuronopathic Gaucher disease. It is also developing '
                        'PR006 for the treatment of frontotemporal dementia '
                        'with GRN mutation; and PR004 for the treatment of '
                        'synucleinopathies. Prevail Therapeutics Inc. was '
                        'founded in 2017 and is based in New York, New York.',
 'longName': 'Prevail Therapeutics Inc.',
 'market': 'us_market',
 'marketCap': 535256576,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_555268516',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -71818000,
 'nextFiscalYearEnd': 1640908800,
 'open': 15.52,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': -1.34,
 'phone': '917 336 9310',
 'previousClose': 15.65,
 'priceHint': 2,
 'priceToBook': 2.9318097,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 15.82,
 'regularMarketDayLow': 15.3,
 'regularMarketOpen': 15.52,
 'regularMarketPreviousClose': 15.65,
 'regularMarketPrice': 15.52,
 'regularMarketVolume': 72350,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 34201700,
 'sharesPercentSharesOut': 0.061,
 'sharesShort': 2087832,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 1365274,
 'shortName': 'Prevail Therapeutics Inc.',
 'shortPercentOfFloat': 0.1271,
 'shortRatio': 7.17,
 'startDate': None,
 'state': 'NY',
 'strikePrice': None,
 'symbol': 'PRVL',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -2.652,
 'twoHundredDayAverage': 15.608956,
 'volume': 72350,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.prevailtherapeutics.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '10016'}